Patterns of Recurrence and Survival After Pelvic Treatment for Locally Advanced Penile Cancer

Reply to Y.-N. Feng et al

“…2 In this phase II trial, patients with stage IV penile cancer were treated with atezolizumab (anti-PD-L1) with or without radiotherapy (RT).Patients with penile cancer with locoregional metastasis experience a high rate of metastasis-associated morbidity and often have rapid progression. 3,4 We, therefore, felt that therapy aimed at locoregional control was needed in the subset of patients at risk for locoregional progression. At the time of trial conception, our standard of care for the treatment of patients with penile cancer with locoregional metastases was chemoradiation of the penis, inguinal, and pelvic lymph nodes.…”